Image: Courtesy of Aclara Biosciences

The eTag™ system from ACLARA BioSciences of Mountain View, Calif., enables the multiplexed, solution-phase analysis of proteins and nucleic acids. This technology employs the company's eTag reporters, which are low-molecular weight, fluorescent molecules that are readily separated and quantified by capillary electrophoresis (CE) in conjunction with fluorescence detection using standard capillary DNA sequencers. This method can be used for any application to simultaneously quantify multiple protein or nucleic acid targets. Its potential for multiplexing will make it attractive to researchers performing proteomic and genomic analyses, including those in drug discovery and development.

"Finding candidate therapeutic targets and potential structural leads no longer represents major hurdles in drug discovery. Today's challenge is to select the most promising targets and leads from an already extensive and rapidly growing number of alternatives," comments Jon Miller, ACLARA's director of corporate development. "To improve the quality of their selections,...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?